StockData
Zivo Bioscience, Inc. logo

Zivo Bioscience, Inc. (ZIVO) stock

ZIVOOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2025, quý kết thúc ngày Sep 30, 2025Last filing: 10-Q on Nov 14, 2025Score 1/30
$6.80+0.30 (+4.62%)

Close on Oct 19, 2026Market cap $25.96MP/E –Yield –

Zivo Bioscience, Inc. grew revenue 164.5% to $209.03K over the twelve months to Sep 30, 2025. At the latest close the market valued the company at $25.96M.

Revenue
$209.03K
+164.5% vs. a year earlier
Operating income
-$8.46M
TTM Q3 2025
EPS, diluted
-$2.27
TTM Q3 2025

Key statistics

Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2025

Valuation

Market cap
$25.96M
P/E ratio
–
Price to sales
124.18
Price to book
–
Dividend yield
–
Free cash flow yield
–

Fundamentals

Revenue
$209.03K
Net income
-$8.49M
EPS, diluted
-$2.27
Book value per share
-$0.86
Diluted shares
4M

Trading

Previous close
$6.50
Open
$6.50
Day's range
$6.50 – $6.80
Volume
1,096
Average volume (20 days)
1,432

Market cap history

Month-end market cap since 2011, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.

PeriodZIVOS&P 500DifferenceZIVO per yearS&P 500 per year
1 month+112.5%+0.6%+111.9 pts
3 months+64.3%+3.4%+60.9 pts
Year to date-21.8%+13.3%−35.1 pts
1 year-45.6%+16.6%−62.3 pts
3 years+61.9%+86.4%−24.5 pts+17.4%+23.1%
5 years-71.6%+81.9%−153.4 pts-22.3%+12.7%
10 years-79.8%+318.9%−398.6 pts-14.8%+15.4%

Fifteen years at a glance

Fiscal years 2010 to 2024 and trailing twelve months, USD

Revenue

$209.03K+164.5% YoY

Gross profit

$66.21K+153.8% YoY

Operating income

-$8.46M

Net income

-$8.49M

EPS, diluted

-$2.27

Free cash flow

–
Reported periodTrailing twelve months

Press releases

Releases Zivo Bioscience filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Zivo Bioscience

Biological Products, (No Diagnostic Substances)

Zivo Bioscience, Inc. operates as a research and development company focused on the biotechnology and agtech sectors. The company centers its operations on two core segments: therapeutics and nutrition, utilizing proprietary algal and bacterial cultures. In the biotech therapeutic segment, it develops bioactive molecules and extracts to combat animal and human health conditions, including poultry coccidiosis, avian influenza, and bovine mastitis. In the agtech nutrition segment, the company produces dried green algae powder for human consumption as a whole food product or functional dietary ingredient. Zivo targets partnerships with established animal health companies for licensing and commercialization, while distributing its nutrition products through third-party marketing and direct-to-consumer platforms.

Company profile, executives and history

Zivo Bioscience stock: common questions

What is Zivo Bioscience's stock price?

ZIVO closed at $6.80 on Oct 19, 2026, up 4.62% on the day.

What is Zivo Bioscience's market cap?

Zivo Bioscience was worth $25.96M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.

What is ZIVO's P/E ratio?

Zivo Bioscience lost money over the twelve months to Sep 30, 2025 (diluted EPS -$2.27), so it has no meaningful P/E ratio.

How much revenue does Zivo Bioscience make?

Zivo Bioscience reported revenue of $209.03K for the twelve months to Sep 30, 2025, up 164.5% from a year earlier.

Does Zivo Bioscience pay a dividend?

No. Zivo Bioscience has not paid a cash dividend over the last twelve months.

How has ZIVO stock performed over the past year?

Including dividends, ZIVO returned -45.6% over the past year, against +16.6% for the S&P 500.

Who are Zivo Bioscience's competitors?

Companies most similar to Zivo Bioscience by business, industry and size include ATYR, ABPO, ARTV, PALI, VIVS.

See a number that looks wrong?